Relationship between Circulating and Tissue microRNAs in a Murine Model of Breast Cancer

MiRNAs are key regulators of tumorigenesis that are aberrantly expressed in the circulation and tissue of patients with cancer. The aim of this study was to determine whether miRNA dysregulation in the circulation reflected similar changes in tumour tissue. Athymic nude mice (n = 20) received either a mammary fat pad (n = 8, MFP), or subcutaneous (n = 7, SC) injection of MDA-MB-231 cells. Controls received no tumour cells (n = 5). Tumour volume was monitored weekly and blood sampling performed at weeks 1, 3 and 6 following tumour induction (total n = 60). Animals were sacrificed at week 6 and tumour tissue (n = 15), lungs (n = 20) and enlarged lymph nodes (n = 3) harvested. MicroRNAs were extracted from all samples (n = 98) and relative expression quantified using RQ-PCR. MiR-221 expression was significantly increased in tumour compared to healthy tissue (p<0.001). MiR-10b expression was significantly higher in MFP compared to SC tumours (p<0.05), with the highest levels detected in diseased lymph nodes (p<0.05). MiR-10b was undetectable in the circulation, with no significant change in circulating miR-221 expression detected during disease progression. MiR-195 and miR-497 were significantly decreased in tumour tissue (p<0.05), and also in the circulation of animals 3 weeks following tumour induction (p<0.05). At both tissue and circulating level, a positive correlation was observed between miR-497 and miR-195 (r = 0.61, p<0.001; r = 0.41, p<0.01 respectively). This study highlights the distinct roles of miRNAs in circulation and tissue. It also implicates miRNAs in disease dissemination and progression, which may be important in systemic therapy and biomarker development.

[1]  Hong Cao,et al.  miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. , 2012, International journal of oncology.

[2]  K. Mimori,et al.  MicroRNA-10b is a Prognostic Indicator in Colorectal Cancer and Confers Resistance to the Chemotherapeutic Agent 5-Fluorouracil in Colorectal Cancer Cells , 2012, Annals of Surgical Oncology.

[3]  Jiao-Yang Li,et al.  MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2 , 2012, Medical Oncology.

[4]  F. Yu,et al.  Plasma miR-221 as a Predictive Biomarker for Chemoresistance in Breast Cancer Patients who Previously Received Neoadjuvant Chemotherapy , 2011, Oncology Research and Treatment.

[5]  K. Ohuchida,et al.  MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. , 2011, Surgery.

[6]  George A Calin,et al.  MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer , 2011, Genome Medicine.

[7]  M. Irigoyen,et al.  MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. , 2011, Physiological genomics.

[8]  Bing-Hua Jiang,et al.  Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast Cancer , 2011, Clinical Cancer Research.

[9]  Y. Liu,et al.  MicroRNA expression signature in atrial fibrillation with mitral stenosis. , 2011, Physiological genomics.

[10]  Stefan Holdenrieder,et al.  Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer , 2011, Tumor Biology.

[11]  S. Brant,et al.  Peripheral blood MicroRNAs distinguish active ulcerative colitis and Crohn's disease , 2011, Inflammatory bowel diseases.

[12]  Muneesh Tewari,et al.  MiR‐221 and MiR‐222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival , 2010, Genes, chromosomes & cancer.

[13]  Michael J Kerin,et al.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. , 2010, The oncologist.

[14]  D. Mukhopadhyay,et al.  Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. , 2010, Blood.

[15]  Michael J Kerin,et al.  Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer , 2010, Annals of surgery.

[16]  A. Munshi,et al.  MicroRNA Signatures in Neurological Disorders , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[17]  Robert A. Weinberg,et al.  Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model , 2010, Nature Biotechnology.

[18]  L. Tanoue Cancer Statistics, 2009 , 2010 .

[19]  S. Lowe,et al.  miR-221 overexpression contributes to liver tumorigenesis , 2009, Proceedings of the National Academy of Sciences.

[20]  G. Schratt,et al.  microRNA involvement in developmental and functional aspects of the nervous system and in neurological diseases , 2009, Neuroscience Letters.

[21]  Xiaohua Li,et al.  Survival prediction of gastric cancer by a seven-microRNA signature , 2009, Gut.

[22]  J. Chi,et al.  MicroRNA expression in chronic lymphocytic leukaemia , 2009, British journal of haematology.

[23]  M. Barcinski,et al.  Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. , 2009, Cancer letters.

[24]  M. Duffy,et al.  Serum tumour markers: how to order and interpret them , 2009, BMJ : British Medical Journal.

[25]  Ulus Atasoy,et al.  Circulating microRNAs in breast cancer and healthy subjects , 2009, BMC Research Notes.

[26]  Jacopo Meldolesi,et al.  Shedding microvesicles: artefacts no more. , 2009, Trends in cell biology.

[27]  T. Hibi,et al.  The role of microRNAs in gastrointestinal cancers , 2009, Journal of Gastroenterology.

[28]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[29]  Carme Camps,et al.  MicroRNA-10b and breast cancer metastasis , 2008, Nature.

[30]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[31]  Massimo Negrini,et al.  Breast cancer metastasis: a microRNA story , 2008, Breast Cancer Research.

[32]  D. Medina,et al.  Re-evaluation of mammary stem cell biology based on in vivo transplantation , 2008, Breast Cancer Research.

[33]  Michael J Kerin,et al.  MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management , 2008, Clinical Cancer Research.

[34]  U. Lehmann,et al.  Epigenetic inactivation of microRNA gene hsa‐mir‐9‐1 in human breast cancer , 2008, The Journal of pathology.

[35]  N. Miller,et al.  Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer , 2008, BMC Molecular Biology.

[36]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.

[38]  Donald Hedeker,et al.  Analysis of binary outcomes with missing data: missing = smoking, last observation carried forward, and a little multiple imputation. , 2007, Addiction.

[39]  C. Croce,et al.  MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. , 2007, Endocrine-related cancer.

[40]  Giovanni Vanni Frajese,et al.  miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1* , 2007, Journal of Biological Chemistry.

[41]  H. Kaplan,et al.  Disease-specific survival in patient-detected breast cancer. , 2006, Clinical breast cancer.

[42]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[43]  M. Duffy,et al.  Serum tumor markers in breast cancer: are they of clinical value? , 2006, Clinical chemistry.

[44]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[46]  C. Croce,et al.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Afonso,et al.  Analysis and optimal design of plates and shells under dynamic loads – II: optimization , 2004 .

[48]  D. Miglioretti,et al.  Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography , 2003, Annals of Internal Medicine.

[49]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[51]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[52]  Los Angeles,et al.  in Civil Engineering , 1996 .

[53]  C Huang,et al.  Optimum design of composite laminated plates via a multi-objective function , 1995 .

[54]  J. Price,et al.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. , 1990, Cancer research.

[55]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.